Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Molecular Subtypes

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Molecular Subtypes — Trials · CancerIndex

Clinical trials

Registered studies

5 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 5
Recruiting: 3
Ph III recruiting: 0
Growth YoY: —
Industry share: 20%
Top sponsor: Memorial Sloan Kettering Cancer Center
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (0)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06830031	Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma(C402)	recruiting	Phase 1	18	Shanghai Exuma Biotechnology Ltd.INDUSTRY	1	Sep 11, 2026	clinicaltrials

Data updated 18 days agoSource updated Sep 11, 2026source: clinicaltrials